Wren Capital

"We are pleased to welcome on board our new investors and appreciate their confidence in our business. Our aim is to replicate the specificity of biologics in the powerful and scalable form of a small molecule, to treat devastating diseases where there are currently no treatment options. We have proven the strength of our platform in tapping unexplored parts of the chemical universe to find novel and specific hits for currently undruggable targets, and are excited to now be able to invest in our own pipeline of drug discovery programmes, as well as to develop further strategic partnerships."

"this funding has come about as a result of the excellent work of the Keit team in developing the technology and the unambiguously positive reaction from the trial work with customers. We are delighted to have a supportive set of like-minded institutions backing our development and growth."